AI Article Synopsis
- CBD vaping products have gained popularity in the U.S. since their legalization in 2018, but their effects on respiratory health are largely unknown.
- Research shows that these products create a reactive substance called CBD quinone (CBDQ) that interacts with proteins in the body.
- The study indicates that CBD vaping may disrupt protein function and trigger stress response pathways in lung cells, raising concerns about its impact on lung health.
Article Abstract
Cannabidiol (CBD) vaping products have become widely available in the U.S. since their legalization in 2018. However, little is known about their respiratory health effects. Here we show that aerosolization of commercial CBD vaping products generates a reactive CBD quinone (CBDQ) which forms adducts with protein cysteine residues. Using click chemistry and a novel vaping product exposure system (VaPES), we further demonstrate that CBDQ forms adducts with human bronchial epithelial cell proteins including Keap1 and activates KEAP1-Nrf2 stress response pathway genes. These results suggest that vaping CBD alters protein function and induces cellular stress pathways in the lung.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10966663 | PMC |
| http://dx.doi.org/10.1021/acs.chemrestox.3c00038 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!